invest1 distinct publisher
Veradermics' 500% run prices a hair-loss launch still more than a year away
Money leaving GLP-1 names for hair-loss biotech is a bet that aesthetic, cash-pay indications carry drug margins without payer risk. The multiples on Veradermics, Absci and Cosmo already assume the approvals.
Publishers:fortune.com
Reality
- Evidence34
- Adoption7
- Hype gap+58
- Incentives79